-
Mashup Score: 2
Thea Pharma announced the presentation of phase 3 data on Iyuzeh (latanoprost ophthalmic solution 0.005%) by Jason Bacharach, MD, at th
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 0Glaucoma Research Foundation to Recognize Santen Pharmaceutical at Annual Gala in San Francisco - Eyewire+ - 1 year(s) ago
Santen Pharmaceutical will receive the Glaucoma Research Foundation’s Catalyst Award at the Glaucoma 360 Annual Gala on February 2, 2023
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
.@SantenUSA will receive the @GlaucomaOrg's Catalyst Award at the #Glaucoma 360 Annual Gala on February 2, 2023, in San Francisco, the foundation's President and CEO Thomas Brunner announced. https://t.co/N9LigKe8S8
-
-
Mashup Score: 2Johns Hopkins Researchers Explore Why Episodes of Low Blood Sugar Worsen Eye Disease in People with Diabetes - Eyewire+ - 1 year(s) ago
Researchers at Johns Hopkins Medicine say they have linked low blood sugar levels in people with diabetes with a molecular pathway that is turned on i
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
Researchers at @HopkinsMedicine say they have linked low #bloodsugar levels in people with #diabetes with a molecular pathway that is turned on in oxygen-starved cells in the eye. https://t.co/oo5zwfKGUL via @eyewireplus
-
-
Mashup Score: 2
Eyenovia announced results from a research study conducted in collaboration with Pedram Hamrah, MD, Interim Chairman of Ophthalmology at Tuf
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
.@eyenovia announced results from a research study which evaluated the gene & protein expression of cytokines & chemokines after latanoprost+BAK treatment administered via #Optejet versus latanoprost+BAK administered via standard eye drops. https://t.co/3PfNwcicv6 https://t.co/PYi8hNuwF2
-
-
Mashup Score: 0
Lumibird Medical announced the launch of their next generation YAG/SLT laser, the Tango Reflex Neo, by Ellex. A fully integrated Q-switch
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
Lumibird Medical announced the launch of their next generation YAG/SLT laser, the Tango Reflex Neo, by Ellex. https://t.co/F1q9SEx791 https://t.co/NC1MFF2eeV
-
-
Mashup Score: 9Bausch + Lomb and Glaucoma Research Foundation Announce Launch of "Screen, Protect, Cure" Campaign - Eyewire+ - 1 year(s) ago
Bausch + Lomb and Glaucoma Research Foundation (GRF) announced the US launch of “Screen, Protect, Cure,” a campaign designed to pr
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
.@BauschLomb and @GlaucomaOrg announce the US launch of "Screen, Protect, Cure," a campaign designed to provide educational resources and raise awareness of #glaucoma during #GlaucomaAwarenessMonth. https://t.co/FPd70zKufH https://t.co/Kmo5RW7cph
-
-
Mashup Score: 0
An international team led by Harvard Medical School scientists at Mass Eye and Ear and Boston Children’s Hospital has discovered a new genetic m
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
An international team led by @harvardmed scientists at @MassEyeAndEar and @BostonChildrens has discovered a new genetic mutation that may be a root cause of severe cases of childhood #glaucoma, according to a @Harvard research report. https://t.co/NEBZWyWufN https://t.co/N1BwrpQHgU
-
-
Mashup Score: 0Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis - Eyewire+ - 1 year(s) ago
Ocugen announced that the FDA granted orphan drug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
.@Ocugen announces FDA grants #orphandrug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3)—for the treatment of #retinitispigmentosa (RP) and Leber congenital amaurosis (LCA). https://t.co/mjMnYjfnuv https://t.co/NSgcUOlp2i
-
-
Mashup Score: 1Visiox Pharma Announces FDA Acceptance of NDA for Glaucoma Drug Candidate - Eyewire+ - 1 year(s) ago
Visiox Pharma announced that it has received notification from the FDA that the agency has completed its filing review and accepted for fili
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
.@Visioxpharma announces it has received notification from the FDA that the agency has completed its filing review and accepted for filing the NDA for PDP-716 (0.35% brimonidine tartrate) for the treatment of #glaucoma. https://t.co/1Bzha7d24G
-
-
Mashup Score: 1Genentech Launches Phase 2a Study of RG6501 (OpRegen) in Patients With Geographic Atrophy - Eyewire+ - 1 year(s) ago
Lineage Cell Therapeutics announced that its partner Genentech has launched a phase 2a, multicenter, open-label, single arm c
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
JUST IN: @LineageCell Therapeutics announced that its partner @genentech has launched a phase 2a, multicenter, open-label, single arm clinical study of RG6501 (OpRegen), a retinal pigment #epithelialcell therapy. #geographicatrophy #AMD https://t.co/RJYeHgIcEP https://t.co/MM6FtJggwr
-
The large, pivotal clinical trial demonstrated comparable efficacy of preservative-free Iyuzeh over brand-name Xalatan containing the preservative benzalkonium chloride (BAK), in patients with primary open-angle #glaucoma or #ocularhypertension. https://t.co/fmUKSfbIow